In vitro evaluation of functional interaction of integrin αvβ3 and matrix metalloprotease-2

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1856-1867

  Vartak, Deepali G ^a   Lee, Bao Shiang ^a   Gemeinhart, Richard A ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

Author keywords

v 3; Angiogenesis; HUVEC; Integrin; Matrix metalloprotease; MMP 2; Molecular targets; RGD peptide

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; DOXORUBICIN; GELATINASE A; VITRONECTIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CELL CULTURE; CELL SURFACE; CONJUGATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF;

AMINO ACID MOTIFS; CELL LINE; CELL SURVIVAL; HUMANS; INTEGRIN ALPHAVBETA3; MATRIX METALLOPROTEINASE 2; MODELS, BIOLOGICAL; PEPTIDES; PROTEIN BINDING;

EID: 71949094817     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900152t     Document Type: Article

References (51)

1. Minko, T.; Dharap, S. S.; Pakunlu, R. I.; Wang, Y. Molecular Targeting of Drug Delivery Systems to Cancer. Curr. Drug Targets 2004, 5 (4), 389-406. (Pubitemid 38559349)
2. Saul, J. M.; Annapragada, A. V.; Bellamkonda, R. V. A Dual-Ligand Approach for Enhancing Targeting Selectivity of Therapeutic Nanocarriers. J. Controlled Release 2006, 114 (3), 277-287
3. Folkman, J. Opinion - Angiogenesis: An Organizing Principle for Drug Discovery. Nat. Rev. Drug Discovery 2007, 6 (4), 273-286 (Pubitemid 46505878)
4. Ruoslahti, E. Rgd and Other Recognition Sequences for Integrins. Annu. Rev. Cell Dev. Biol. 1996, 12, 697-715.
5. Smith, J. W.; Cheresh, D. A. Integrin (Alpha-V-Beta-3)-Ligand Interaction - Identification of a Heterodimeric Rgd Binding-Site on the Vitronectin Receptor. J. Biol. Chem. 1990, 265 (4), 2168-2172 (Pubitemid 20248325)
6. Avraamides, C. J.; Garmy-Susini, B.; Varner, J. A. Integrins in Angiogenesis and Lymphangiogenesis. Nat. Rev. Cancer 2008, 8, 604-617
7. Brooks, P. C.; Clark, R. A. F.; Cheresh, D. A. Requirement of Vascular Integrin Alpha(V)Beta(3) for Angiogenesis. Science 1994, 264 (5158), 569-571
8. Hersey, P.; Sosman, J.; O'Day, S.; Richards, J.; Bedikian, A.; Gonzalez, R.; Sharfman, W.; Weber, R.; Logan, T.; Kirkwood, J. M. A Phase II, Randomized, Open-Label Study Evaluating the Antitumor Activity of Medi-522, a Humanized Monoclonal Antibody Directed against the Human Alpha V Beta 3 (αvβ3) Integrin, ± Dacarbazine (DTIC) in Patients with Metastatic Melanoma (MM). J. Clin. Oncol. 2005, 23 (16), 711S.
9. Nabors, L. B.; Mikkelsen, T.; Rosenfeld, S. S.; Hochberg, F.; Akella, N. S.; Fisher, J. D.; Cloud, G. A.; Zhang, Y.; Carson, K.; Wittemer, S. M.; Colevas, A. D.; Grossman, S. A. Phase I and Correlative Biology Study of Cilengitide in Patients with Recurrent Malignant Glioma. J. Clin. Oncol. 2007, 25 (13), 1651-1657
10. Liu, S. Radiolabeled Multimeric Cyclic Rgd Peptides as Integrin Alpha(V)Beta(3) Targeted Radiotracers for Tumor Imaging. Mol. Pharmaceutics 2006, 3 (5), 472-487 (Pubitemid 44639125)
11. von Wallbrunn, A.; Holtke, C.; Zuhlsdorf, M.; Heindel, W.; Schafers, M.; Bremer, C. In Vivo Imaging of Integrin Alpha Nu Beta(3) Expression Using Fluorescence-Mediated Tomography. Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (5), 745-754 (Pubitemid 46669357)
12. Temming, K.; Schiffelers, R. M.; Molema, G.; Kok, R. J. Rgd-Based Strategies for Selective Delivery of Therapeutics and Imaging Agents to the Tumour Vasculature. Drug Resist. Updates 2005, 8 (6), 381-402.
13. Brinckerhoff, C. E.; Matrisian, L. M. Matrix Metalloproteinases: A Tail of a Frog That Became a Prince. Nat. Rev. Mol. Cell Biol. 2002, 3 (3), 207-214
14. Rundhaug, J. E. Matrix Metalloproteinases and Angiogenesis. J. Cell. Mol. Med. 2005, 9 (2), 267-285
15. Kalebic, T.; Garbisa, S.; Glaser, B.; Liotta, L. A. Basement-Membrane Collagen - Degradation by Migrating Endothelial-Cells. Science 1983, 221 (4607), 281-283
16. McCawley, L. J.; Matrisian, L. M. Matrix Metalloproteinases: They're Not Just for Matrix Anymore! Curr. Opin. Cell Biol. 2001, 13 (5), 534-540
17. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99 (9), 2735-2776
18. Coussens, L. M.; Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295 (5564), 2387-2392 (Pubitemid 34270240)
19. Fingleton, B. Matrix Metalloproteinase Inhibitors for Cancer Therapy: The Current Situation and Future Prospects. Expert Opin. Ther. Targets 2003, 7 (3), 385-397 (Pubitemid 36722223)
20. Overall, C. M.; Kleifeld, O. Tumour Microenvironment - Opinion - Validating Matrix Metalloproteinases as Drug Targets and Anti-Targets for Cancer Therapy. Nat Rev Cancer 2006, 6 (3), 227-239
21. Atkinson, J. M.; Siller, C. S.; Gill, J. H. Tumour Endoproteases: The Cutting Edge of Cancer Drug Delivery? Br. J. Pharmacol. 2008, 153 (7), 1344-1352
22. Vartak, D. G.; Gemeinhart, R. A. Matrix Metalloproteases: Underutilized Targets for Drug Delivery. J. Drug Targeting 2007, 15 (1), 1-20.
23. Lafleur, M. A.; Tester, A. M.; Thompson, E. W. Selective Involvement of Timp-2 in the Second Activational Cleavage of Pro-Mmp-2: Refinement of the Pro-Mmp-2 Activation Mechanism. FEBS Lett. 2003, 553 (3), 457-463
24. Deryugina, E. I.; Ratnikov, B.; Monosov, E.; Postnova, T. I.; DiScipio, R.; Smith, J. W.; Strongin, A. Y. Mt1-Mmp Initiates Activation of Pro-Mmp-2 and Integrin Alpha V Beta 3 Promotes Maturation of Mmp-2 in Breast Carcinoma Cells. Exp. Cell Res. 2001, 263 (2), 209-223
25. Silletti, S.; Cheresh, D. A. A Link between Integrins and Mmps in Angiogenesis. Fibrinolysis Proteolysis 1999, 13 (6), 226-238
26. Partridge, C. A.; Phillips, P. G.; Niedbala, M. J.; Jeffrey, J. J. Localization and Activation of Type Iv Collagenase/Gelatinase at Endothelial Focal Contacts. Am. J. Physiol. 1997, 272 (5), L813-L22.
27. Monsky, W. L.; Kelly, T.; Lin, C. Y.; Yeh, Y. Y.; Stetlerstevenson, W. G.; Mueller, S. C.; Chen, W. T. Binding and Localization of M(R)-72,000 Matrix Metalloproteinase at Cell-Surface Invadopodia. Cancer Res. 1993, 53 (13), 3159-3164
28. Deryugina, E. I.; Bourdon, M. A.; Luo, G. X.; Reisfeld, R. A.; Strongin, A. Matrix Metalloproteinase-2 Activation Modulates Glioma Cell Migration. J. Cell Sci. 1997, 110, 2473-2482 (Pubitemid 127699161)
29. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J. P.; Carroll, R. S.; Nikas, D. C.; Strasser, J. F.; Villani, R.; Cheresh, D. A.; Black, P. M. Alpha V Beta 3 and Alpha V Beta 5 Integrin Expression in Glioma Periphery. Neurosurgery 2001, 49 (2), 380-389
30. Puyraimond, A.; Fridman, R.; Lemesle, M.; Arbeille, B.; Menashi, S. Mmp-2 Colocalizes with Caveolae on the Surface of Endothelial Cells. Exp. Cell Res. 2001, 262 (1), 28-36. (Pubitemid 32989005)
31. Brooks, P. C.; Silletti, S.; von Schalscha, T. L.; Friedlander, M.; Cheresh, D. A. Disruption of Angiogenesis by Pex, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity. Cell 1998, 92 (3), 391-400.
32. Brooks, P. C.; Stromblad, S.; Sanders, L. C.; vonSchalscha, T. L.; Aimes, R. T.; StetlerStevenson, W. G.; Quigley, J. P.; Cheresh, D. A. Localization of Matrix Metalloproteinase Mmp-2 to the Surface of Invasive Cells by Interaction with Integrin Alpha V Beta 3. Cell 1996, 85 (5), 683-693
33. Pfeifer, A.; Kessler, T.; Silletti, S.; Cheresh, D. A.; Verma, I. M. Suppression of Angiogenesis by Lentiviral Delivery of Pex, a Noncatalytic Fragment of Matrix Metalloproteinase 2. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (22), 12227-12232
34. Silletti, S.; Kessler, T.; Goldberg, J.; Boger, D. L.; Cheresh, D. A. Disruption of Matrix Metalloproteinase 2 Binding to Integrin Alpha(V)Beta(3) by an Organic Molecule Inhibits Angiogenesis and Tumor Growth in Vivo. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (1), 119-124
35. Nisato, R. E.; Hosseini, G.; Sirrenberg, C.; Butler, G. S.; Crabbe, T.; Docherty, A. J. P.; Wiesner, M.; Murphy, G.; Overall, C. M.; Goodman, S. L.; Pepper, M. S. Dissecting the Role of Matrix Metalloproteinases (Mmp) and Integrin Alpha(V)Beta(3) in Anglogenesis in Vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-Mmp and Alpha(V)Beta(3) Are Critical. Cancer Res. 2005, 65 (20), 9377-9387
36. Ryppa, C.; Mann-Steinberg, H.; Fichtner, I.; Weber, H.; Satchi-Fainaro, R.; Biniossek, M. L.; Kratz, F. In Vitro and in Vivo Evaluation of Doxorubicin Conjugates with the Divalent Peptide E-[C(Rgdfk)(2)] That Targets Integrin Alpha(V)Beta(3). Bioconjugate Chem. 2008, 19 (7), 1414-1422 (Pubitemid 352032341)
37. Bremer, C.; Tung, C. H.; Weissleder, R. In Vivo Molecular Targe t Assessment of Matrix Metalloproteinase Inhibition. Nat. Med. 2001, 7 (6), 743-748 (Pubitemid 32588033)
38. von Maltzahn, G.; Harris, T. J.; Park, J. H.; Min, D. H.; Schmidt, A. J.; Sailor, M. J.; Bhatia, S. N. Nanoparticle Self-Assembly Gated by Logical Proteolytic Triggers. J. Am. Chem. Soc. 2007, 129 (19), 6064.
39. Beeton, C.;Wulff, H.; Singh, S.; Botsko, S.; Crossley, G.; Gutman, G. A.; Cahalan, M. D.; Pennington, M.; Chandy, K. G. A Novel Fluorescent Toxin to Detect and Investigate Kv1.3 Channel up-Regulation in Chronically Activated T Lymphocytes. J. Biol. Chem. 2003, 278 (11), 9928-9937
40. Mitra, A.; Mulholland, J.; Nan, A.; McNeill, E.; Ghandehari, H.; Line, B. R. Targeting Tumor Angiogenic Vasculature Using Polymer-Rgd Conjugates. J. Controlled Release 2005, 102 (1), 191-201. (Pubitemid 40093785)
41. Alvarez-Iglesias, M.; Wayne, G.; O'Dea, K. P.; Amour, A.; Takata, M. Continuous Real-Time Measurement of Tumor Necrosis Factor-Alpha Converting Enzyme Activity on Live Cells. Lab. Invest. 2005, 85 (11), 1440-1448 (Pubitemid 41509391)
42. Engelman, V. W.; Nickols, G. A.; Ross, F. P.; Horton, M. A.; Griggs, D. W.; Settle, S. L.; Ruminski, P. G.; Teitelbaum, S. L. A Peptidomimetic Antagonist of the Alpha(V)Beta(3) Integrin Inhibits Bone Resorption in Vitro and Prevents Osteoporosis in Vivo. J. Clin. Invest. 1997, 99 (9), 2284-2292
43. Tatin, F.; Varon, C.; Genot, E.; Moreau, V. A Signalling Cascade Involving Pkc, Src and Cdc42 Regulates Podosome Assembly in Cultured Endothelial Cells in Response to Phorbol Ester. J. Cell Sci. 2006, 119 (4), 769-781
44. Steffensen, B.; Bigg, H. F.; Overall, C. M. The Involvement of the Fibronectin Type II-Like Modules of Human Gelatinase a in Cell Surface Localization and Activation. J. Biol. Chem. 1998, 273 (32), 20622-20628
45. Wallon, U. M.; Overall, C. M. The Hemopexin-Like Domain (C Domain) of Human Gelatinase a (Matrix Metalloproteinase-2) Requires Ca2+ for Fibronectin and Heparin Binding - Binding Properties of Recombinant Gelatinase a C Domain to Extracellular Matrix and Basement Membrane Components. J. Biol. Chem. 1997, 272 (11), 7473-7481
46. Galvez, B. G.; Matias-Roman, S.; Albar, J. P.; Sanchez-Madrid, F.; Arroyo, A. G. Membrane Type 1-Matrix Metalloproteinase Is Activated During Migration of Human Endothelial Cells and Modulates Endothelial Motility and Matrix Remodeling. J. Biol. Chem. 2001, 276 (40), 37491-37500 (Pubitemid 37384173)
47. Leu, S. J.; Lam, S. C. T.; Lau, L. F. Pro-Angiogenic Activities of Cyr61 (Ccn1) Mediated through Integrins Alpha(V)Beta(3) and Alpha(6)Beta(1) in Human Umbilical Vein Endothelial Cells. J. Biol. Chem. 2002, 277 (48), 46248-46255
48. Gerspach, J.; Muller, D.; Munkel, S.; Selchow, O.; Nemeth, J.; Noack, M.; Petrul, H.; Menrad, A.; Wajant, H.; Pfizenmaier, K. Restoration of Membrane Tnf-Like Activity by Cell Surface Targeting and Matrix Metalloproteinase- Mediated Processing of a Tnf Prodrug. Cell Death Differ. 2006, 13 (2), 273-284 (Pubitemid 43102210)
49. Watermann, I.; Gerspach, J.; Lehne, M.; Seufert, J.; Schneider, B.; Pfizenmaier, K.;Wajant, H. Activation of Cd95l Fusion Protein Prodrugs by Tumor-Associated Proteases. Cell Death Differ. 2007, 14 (4), 765-774
50. Haubner, R.; Gratias, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H. Structural and Functional Aspects of Rgd-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin Alpha(V)Beta(3) Antagonists. J. Am. Chem. Soc. 1996, 118 (32), 7461-7472
51. Janssen, M.; Oyen, W. J. G.; Massuger, L.; Frielink, C.; Dijkgraaf, I.; Edwards, D. S.; Radjopadhye, M.; Corstens, F. H. M.; Boerman, O. C. Comparison of a Monomeric and Dimeric Radiolabeled Rgd-Peptide for Tumor Targeting. Cancer Biother. Radiopharm. 2002, 17 (6), 641-646